← All trials
NCT05751226
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2023
- Primary completion
- Apr 25, 2024
- Completion date
- Apr 25, 2024
- First posted
- Mar 2, 2023
- Last posted
- Nov 28, 2023
- Enrollment
- 92
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.